For immediate release |
22 June 2010 |
("Alliance" or the "Company")
Major interest in shares
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was today informed that Nigel Wray purchased, on 21 June 2010, 800,000 ordinary shares of 1p each in the Company.
Mr Wray's resultant shareholding is 26,069,995 ordinary shares, equivalent to 11.26% of the Company's issued share capital.
Mr Wray's ordinary shares are held as follows:
Nominee |
Number of ordinary shares |
Pershing Nominees Limited Smith & Williamson Nominees Limited Roy Nominees Limited
|
9,405,407 50,000 16,614,588 |
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
John Dawson, Chief Executive Officer |
|
Richard Wright, Finance Director |
|
www.alliancepharma.co.uk |
|
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
Mark Court / Stasa Filiplic |
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Brent Nabbs |
|
Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed both to hospitals directly and to pharmaceutical wholesalers, which in turn service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.